WO1998027929A2 - Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder - Google Patents
Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder Download PDFInfo
- Publication number
- WO1998027929A2 WO1998027929A2 PCT/DE1997/003032 DE9703032W WO9827929A2 WO 1998027929 A2 WO1998027929 A2 WO 1998027929A2 DE 9703032 W DE9703032 W DE 9703032W WO 9827929 A2 WO9827929 A2 WO 9827929A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic
- estradiol
- treatment
- pmdd
- estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the present invention relates to the use of therapeutic gestagens for the treatment of premenstrual dysphoric disorder (PMDD).
- PMDD premenstrual dysphoric disorder
- PMDD is manifested by the appearance of at least 5 of the 11 symptoms listed below, these must be severe premenstrual and submenually subside. These 5 symptoms must include at least one dysphoric symptom (irritability, mood swings, anxiety or depression). Multiple physical symptoms are counted as one symptom.
- Criteria for the presence of premenstrual dysphoric disorder In the prospective evaluation by recording the symptoms by the patient over 2 or 3 menstrual cycles, 5 (or more) of the symptoms listed below occur during the last week of the luteal phase, but no longer occur postmenstrually. At least one of the symptoms must be the 1st, 2nd, 3rd or 4th symptom below.
- the listed disorders must noticeably impair work, school or normal social activities and relationships with others.
- the 10 disorders should not be an aggravation of the symptoms of other disorders (e.g. major depressive disorder, panic disorder, dysthymic personality disorder).
- PMDD premenstrual symptom
- SSRIs serotonin reuptake inhibitors
- other psychotropic agents e.g. alprazolam
- Treatment with these compounds can cause serious side effects; in addition, only part of the symptoms that make up the 3 clinical picture PMDD can be alleviated with psychotropic active substances.
- the object of the present invention is to provide an effective medicament for the treatment of PMDD which avoids the disadvantages of the medicaments used hitherto.
- progestogens can be used in the manufacture of medicaments for the treatment of PMDD. This is very surprising since hormonal treatments have been considered but have not proven to be helpful.
- Therapeutic progestogens are to be understood as those progestogens which, in addition to their progestogen activity, have a favorable profile for therapeutic purposes, ie which additionally have an antiandrogenic and, if appropriate, also an antimineralcorticoid effect occurs
- Examples of such therapeutic progestogens to be used according to the invention are cyproterone acetate, dienogest and, in particular, drospirenone. While the first two have a gestagenic and antiandrogenic effect, drospirenone, like natural progesterone, has an additional antimineralcorticoid activity
- progestin drospirenone Due to the antimineralcorticoid properties of the progestin drospirenone, there is relief from physical symptoms such as breast tenderness or distension,
- a medicament according to the invention can contain either a therapeutic progestogen alone or a therapeutic progestogen in combination with an estrogen. Both natural and synthetic estrogens are suitable as estrogens.
- the dosage of the therapeutic progestogens should be 0.5 mg to less than 5 mg, preferably 1.0 to 4.0 mg per day in the case of drospirenone or an equivalent amount of another therapeutic progestogen.
- the gestagenic and estrogenic active ingredient components are preferably administered orally together.
- the daily dose is preferably administered once.
- estradiol As natural estrogens, these are in particular estradiol and also its longer-acting esters such as valerate etc. or estriol.
- estrogens such as ethinyl estradiol, 14 ⁇ , 17 ⁇ -ethano-l, 3,5 (10) -estratrien-3,17ß-diol (WO 88/01275), 14, 17 ⁇ -ethano-l, 3,5 (10 ) -estratrien-3, 16 ⁇ , 17ß-triol (WO 91/08219) or the 15,15-dialkyl derivatives of estradiol, and in particular the 15,15-dimethyltradiol.
- Ethinyl estradiol is preferred as the synthetic estrogen.
- estratriene-3-amidosulfonates WO 96/05216 and WO 96/052157, derived from estradiol or ethinyl estradiol, which are characterized by low hapatic estrogenicity, are also suitable as estrogens for use together with the compounds of the general formula I. .
- the estrogen is administered in an amount equal to that of 0.010 to 0.05 mg ethinylestradiol or 1.0 to 3.0 mg daily.
- the pharmaceutical preparations are formulated on the basis of the new compounds in a manner known per se by combining the active ingredient, the therapeutic gestagen, optionally in combination with an estrogen, with those in galenics common carrier substances, diluents, if necessary taste correctives etc., processed and converted into the desired application form.
- Tablets, coated tablets, capsules, pills, suspensions or solutions are particularly suitable for the preferred oral application.
- Oily solutions such as solutions in sesame oil, castor oil and cottonseed oil, are particularly suitable for parenteral administration.
- Solubilizers such as, for example, benzyl benzoate or benzyl alcohol, can be added to increase the solubility.
- the therapeutic progestogen optionally in combination with an estrogen, can also be administered continuously by means of an intrauterine release system (IUD); the release rate of the active compound (s) is chosen so that the daily dose is within the dosage ranges already given.
- IUD intrauterine release system
- a monopreparation containing only a therapeutic progestin it can be designed for the administration of daily dosage units over the entire menstrual cycle.
- the medicament for the treatment of PMDD is administered only during the luteal phase of the cycle, beginning at the earliest with day 10 until the end of the cycle, usually until day 28. Longer administration is also conceivable.
- therapeutic progestin according to the present invention is used in combination preparations together with an estrogen, these preparations can be provided for the continuous, sequential or cyclic administration of the active compounds.
- Continuous administration means the daily administration of both active ingredients together.
- Sequential administration means administration of the therapeutic progestogen from day 10 at the earliest until the end of the cycle.
- the administration from day 10 to 28 is preferably meant here.
- the estrogen is administered together with the progestogen, separately or in the same dosage unit.
- the estrogen is also administered on some or all of the gestagen-free days.
- Cyclic administration means the administration of both active substances from the first day of the cycle to a point in time before the last day of the cycle, preferably day 21 to day 23.
- these preparations are also suitable for contraception if the active components are contained in a sufficient amount for this. These preparations are therefore preferably used for the symptomatic treatment of women of reproductive age with moderate to severe symptoms of PMDD.
- the therapeutic progestin is preferably used with a synthetic estrogen such as ethinyl estradiol.
- Combination preparations of a therapeutic progestogen with a natural estrogen, in particular estradiol can preferably be used for the symptomatic treatment of moderate to severe symptoms of PMDD in perimenopausal women.
- Perimenopause begins with the onset of menopausal symptoms and ends one year after menopause, the last menstrual period.
- the medicament according to the invention can also be used in conjunction with a psychotropic medicament of the type mentioned at the beginning.
- Fertile women who were classified as PMDD patients according to criteria 1 to 11 above are given orally daily with an amount of 3 mg drospirenone together with 30 ⁇ g ethinyl estradiol from at least 4 cycles, from day 1 to day 21 of the cycle treated. This is followed by 7 days without ingestion or 7 daily placebos. After treatment over 4 to 6 cycles, the symptoms belonging to criteria 1 to 11 are carefully evaluated again. Significant improvement in at least one of the symptoms that occurred before treatment, but not only the 11th symptom, was observed in all women treated.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59810/98A AU5981098A (en) | 1996-12-20 | 1997-12-22 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US09/619,493 US6987101B1 (en) | 1996-12-20 | 2000-07-19 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US11/204,035 US20050282790A1 (en) | 1996-12-20 | 2005-08-16 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US11/449,866 US20070111974A1 (en) | 1996-12-20 | 2006-06-09 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US13/039,701 US20120028935A1 (en) | 1996-12-20 | 2011-03-03 | Therapeutic Gestagens for the Treatment of Premenstrual Dysphoric Disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19654609A DE19654609A1 (de) | 1996-12-20 | 1996-12-20 | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
DE19654609.5 | 1996-12-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09331397 A-371-Of-International | 1997-12-22 | ||
US09/619,493 Continuation US6987101B1 (en) | 1996-12-20 | 2000-07-19 | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998027929A2 true WO1998027929A2 (de) | 1998-07-02 |
WO1998027929A3 WO1998027929A3 (de) | 1998-11-05 |
Family
ID=7816356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/003032 WO1998027929A2 (de) | 1996-12-20 | 1997-12-22 | Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder |
Country Status (4)
Country | Link |
---|---|
US (3) | US20050282790A1 (de) |
AU (1) | AU5981098A (de) |
DE (1) | DE19654609A1 (de) |
WO (1) | WO1998027929A2 (de) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
US6869941B2 (en) | 2001-07-13 | 2005-03-22 | Schering Ag | Combination of drospirenone and an estrogen sulphamate for HRT |
US6987101B1 (en) * | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
EP1632237A2 (de) * | 2000-12-20 | 2006-03-08 | Schering Aktiengesellschaft | Zusammensetzungen einschliesslich Drospirenone und einem Komplex zwischen Ethinyl-Estradiol und einem Cyclodextrin |
HRP20020666B1 (en) * | 2000-01-18 | 2011-07-31 | Bayer Schering Pharma Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US8022053B2 (en) | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
US8071577B2 (en) | 2004-04-20 | 2011-12-06 | Bayer Pharma Aktiengesellschaft | Multi-phase contraceptive preparation based on a natural estrogen |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
US8349820B2 (en) | 2006-10-20 | 2013-01-08 | Bayer Pharma Aktiengesellschaft | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido |
HRP20070360B1 (hr) * | 2000-01-18 | 2014-11-21 | Bayer Pharma AG | Drospirenon za hormonsku nadomjesnu terapiju |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19908762A1 (de) * | 1999-02-18 | 2000-08-31 | Jenapharm Gmbh | Verwendung von Dienogest in hoher Dosierung |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
AU2001285318A1 (en) * | 2000-08-28 | 2002-03-13 | Pharmacia Corporation | Use of an aldosterone receptor antagonist to improve cognitive function |
EP1535618A1 (de) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmazeutische Zubereitung zur kontinuierlichen hormonellen Behandlung über einen Zeitraum von über 21-28 Tage beinhaltend zwei Estrogen und/oder Progestin Zusammensetzungen |
CN1972692A (zh) * | 2004-05-26 | 2007-05-30 | 惠氏公司 | 治疗经前焦虑障碍的组合物和方法 |
EP1655031A1 (de) * | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
EP0640343A1 (de) * | 1993-07-01 | 1995-03-01 | Leiras Oy | Oraler Kontrazeptivum enthaltend Estradiolvalerat und Cyproteronacetat |
DE4344462A1 (de) * | 1993-12-22 | 1995-06-29 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US558129A (en) * | 1896-04-14 | Sheet-metal vessel | ||
US5140021A (en) * | 1986-04-16 | 1992-08-18 | Genesis Systems Corporation | Method and dosage form for treatment of premenstrual syndrome |
US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
-
1996
- 1996-12-20 DE DE19654609A patent/DE19654609A1/de not_active Ceased
-
1997
- 1997-12-22 AU AU59810/98A patent/AU5981098A/en not_active Abandoned
- 1997-12-22 WO PCT/DE1997/003032 patent/WO1998027929A2/de active Application Filing
-
2005
- 2005-08-16 US US11/204,035 patent/US20050282790A1/en not_active Abandoned
-
2011
- 2011-03-03 US US13/039,701 patent/US20120028935A1/en not_active Abandoned
-
2013
- 2013-02-01 US US13/757,060 patent/US20130225542A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
EP0640343A1 (de) * | 1993-07-01 | 1995-03-01 | Leiras Oy | Oraler Kontrazeptivum enthaltend Estradiolvalerat und Cyproteronacetat |
DE4344462A1 (de) * | 1993-12-22 | 1995-06-29 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
Non-Patent Citations (1)
Title |
---|
L.L. ALTSHULER ET AL.: "Pharmacological management of premenstrual disorder." HARVARD REV. PSYCHIAT., Bd. 2, Nr. 5, 1995, Seiten 233-245, XP002076665 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6987101B1 (en) * | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
JP2003520239A (ja) * | 2000-01-18 | 2003-07-02 | シェーリング アクティエンゲゼルシャフト | ホルモン置換療法用のドロスピレノン |
HRP20070360B1 (hr) * | 2000-01-18 | 2014-11-21 | Bayer Pharma AG | Drospirenon za hormonsku nadomjesnu terapiju |
AU2001225413B2 (en) * | 2000-01-18 | 2005-06-23 | Bayer Schering Pharma Aktiengesellschaft | Drospirenone for hormone replacement therapy |
EP1611892A2 (de) * | 2000-01-18 | 2006-01-04 | Schering Aktiengesellschaft | Pharmazeutische Zubereitung enthaltend Drospirenon |
EP1611892A3 (de) * | 2000-01-18 | 2006-02-01 | Schering Aktiengesellschaft | Pharmazeutische Zubereitung enthaltend Drospirenon |
HRP20020666B1 (en) * | 2000-01-18 | 2011-07-31 | Bayer Schering Pharma Aktiengesellschaft | Drospirenone for hormone replacement therapy |
KR100747965B1 (ko) * | 2000-01-18 | 2007-08-08 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 호르몬 보충 요법용 드로스피렌온 |
US7163931B2 (en) | 2000-12-20 | 2007-01-16 | Schering Aktiengesellchaft | Compositions of estrogen-cyclodextrin complexes |
EP1632237A3 (de) * | 2000-12-20 | 2006-04-12 | Schering Aktiengesellschaft | Zusammensetzungen einschliesslich Drospirenone und einem Komplex zwischen Ethinyl-Estradiol und einem Cyclodextrin |
EA011275B1 (ru) * | 2000-12-20 | 2009-02-27 | Шеринг Акциенгезельшафт | Суточная дозированная единица комплекса этинилэстрадиол-циклодекстрин |
US7569557B2 (en) | 2000-12-20 | 2009-08-04 | Bayer Schering Pharma Ag | Compositions of estrogen-cyclodextrin complexes |
EP1632237A2 (de) * | 2000-12-20 | 2006-03-08 | Schering Aktiengesellschaft | Zusammensetzungen einschliesslich Drospirenone und einem Komplex zwischen Ethinyl-Estradiol und einem Cyclodextrin |
HRP20070198B1 (hr) * | 2000-12-20 | 2019-04-19 | Bayer Intellectual Property Gmbh | Smjese estrogen-ciklodekstrin kompleksa |
CZ307876B6 (cs) * | 2000-12-20 | 2019-07-10 | Bayer Intellectual Property Gmbh | Denní dávková jednotka obsahující komplex estrogen-cyklodextrin |
US6869941B2 (en) | 2001-07-13 | 2005-03-22 | Schering Ag | Combination of drospirenone and an estrogen sulphamate for HRT |
US8071577B2 (en) | 2004-04-20 | 2011-12-06 | Bayer Pharma Aktiengesellschaft | Multi-phase contraceptive preparation based on a natural estrogen |
US8022053B2 (en) | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
US8349820B2 (en) | 2006-10-20 | 2013-01-08 | Bayer Pharma Aktiengesellschaft | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido |
Also Published As
Publication number | Publication date |
---|---|
US20120028935A1 (en) | 2012-02-02 |
AU5981098A (en) | 1998-07-17 |
WO1998027929A3 (de) | 1998-11-05 |
DE19654609A1 (de) | 1998-06-25 |
US20050282790A1 (en) | 2005-12-22 |
US20130225542A1 (en) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998027929A2 (de) | Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder | |
DE3916112C2 (de) | ||
DE19739916C2 (de) | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
EP0696454B1 (de) | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente | |
EP0148724B1 (de) | Mehrstufenkombinationspräparat und seine Verwendung zur oralen Kontrazeption | |
DE69432752T2 (de) | Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält | |
EP0835114B1 (de) | Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption | |
EP0735882A1 (de) | Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen | |
WO1995026730A1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
DE19705229A1 (de) | Mittel zur hormonalen Kontrazeption | |
DE3022337C2 (de) | ||
US20090137537A1 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
DE4224534A1 (de) | Ovulationshemmendes Mittel zur hormonalen Kontrazeption | |
EP0871453A1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
DE2431704A1 (de) | Stufenkombinationspraeparate per kontrazeption | |
EP1978970B1 (de) | Kontrazeptivum | |
DE2431694A1 (de) | Kontrzeptionsmittel und kontrazeptivumpackung | |
DE19610635A1 (de) | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie | |
EP1655031A1 (de) | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung | |
WO1996028165A1 (de) | Einmonatsspritze als depot-kontrazeptivum und für die hormonersatztherapie für peri- und praemenopausale frauen | |
DE2319850A1 (de) | Verfahren zur fruchtbarkeitskontrolle und abgabepackung zu seiner durchfuehrung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09331397 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |